Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Ahrens

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Scientific Reports|November 30, 2021
Impact of respiratory infectious epidemics on STEMI incidence and careS Macherey, M M Meertens, C Adler, et al.
European Heart Journal. Acute Cardiovascular Care|February 13, 2021
Current status and needs for changes in critical care training: the voice of the young cardiologistsKatarzyna Czerwińska-Jelonkiewicz, Santiago Montero, J Bañeras, et al.
International Journal of Cardiology|August 22, 2018
Droplet digital PCR of serum miR-499, miR-21 and miR-208a for the detection of functionally relevant coronary artery diseaseM Hortmann, J E Walter, L Benning, et al.
ESMO Open|July 16, 2022
Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447]S Ochsenreither, W M Fiedler, G Del Conte, et al.
ESMO Open|April 9, 2022
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumorsS Ochsenreither, W M Fiedler, G D Conte, et al.
ESMO Open|December 17, 2021
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II studyJ A Ledermann, B Zurawski, F Raspagliesi, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Scientific Reports|November 30, 2021
Impact of respiratory infectious epidemics on STEMI incidence and careS Macherey, M M Meertens, C Adler, et al.
European Heart Journal. Acute Cardiovascular Care|February 13, 2021
Current status and needs for changes in critical care training: the voice of the young cardiologistsKatarzyna Czerwińska-Jelonkiewicz, Santiago Montero, J Bañeras, et al.
International Journal of Cardiology|August 22, 2018
Droplet digital PCR of serum miR-499, miR-21 and miR-208a for the detection of functionally relevant coronary artery diseaseM Hortmann, J E Walter, L Benning, et al.
ESMO Open|July 16, 2022
Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447]S Ochsenreither, W M Fiedler, G Del Conte, et al.
ESMO Open|April 9, 2022
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumorsS Ochsenreither, W M Fiedler, G D Conte, et al.
ESMO Open|December 17, 2021
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II studyJ A Ledermann, B Zurawski, F Raspagliesi, et al.
Pageof 3